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ABSTRACT  
The predrug (prodrug) term involves chemically modified inert 
compound which upon an administration releases the active parent 
drug to elicit its pharmacological response within the body. For many 
years, the predrug strategy has been extensively developed to solve 
many unwanted drug properties. This approach has several advantages 
over conventional drug administration and it has the potential to be 
quite effective method for the treatment of diseases in the future. In 
this mini-review we describe a number of antibacterial agents‘ 
predrugs, and the ways by which predrug strategy was exploited to 
overcome many pharmaceutical and pharmacokinetic problems that the 
parent active antibacterial drugs suffer from such as, low  
bioavailability by increasing or decreasing lipophilicity, site selectivity for higher absorption 
and less toxicity, short duration of action to increase patient compliance, rapid  metabolism to 
increase oral bioavailability and masking bitter sensation which is crucial for geriatric and 
pediatric patient compliance. 
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INTRODUCTION 
The prodrug  or more precisely ―predrug‖ term was reported for the first time by Albert as a 
pharmacologically inactive compound which is metabolized to an active form upon 
administration to the body.
[1]
 Predrugs have been successfully used to modify the 
physicochemical and pharmacokinetic properties (absorption, distribution, metabolism and 
excretion, ADME) of drugs and to eliminate or decrease the associated toxicity upon their 
administration.
[2] 
 
Generally, a predrug undergoes chemical and/or enzymatic reaction prior to exert its 
therapeutic activity.
[3]
 Basically, the use of the term predrug implies a chemical entity in 
which a non-toxic promoiety is covalently linked to an active drug.
[4]
 This approach is 
designed to overcome biological and/or biochemical barriers through a chemical approach 
rather than a physical (formulation) approach.
[5-14] 
 
In general, predrugs contain a promoiety (linker) that is cleaved by enzymatic or chemical 
reactions, while other predrugs liberate their active forms after molecular modiﬁcation, such 
as an oxidation or reduction reactions. In other cases, two therapeutically active drugs can be 
attached together in a single molecule named a ―codrug‖. In these cases, each drug acts as a 
linker (promoiety) for the other drug. It is mandatory that the predrug should be 
pharmacologically inactive or weakly active, rapidly converted to its active parent drug and a 
non-toxic moiety by catalyzed or uncatalayzed chemical reaction.  
 
Antibacterials Predrugs 
The first examples of antibacterials predrugs, methenamine and  prontosil , were discovered 
by an accident and their discovery illustrate how serendipity has contributed to predrugs 
development.
[2]
 
 
Methenamine was discovered in 1899 by Schering (Germany) as inactive predrug that upon 
an exposure to the urinary tract releases the antibacterial formaldehyde. This predrug is useful  
in the treatment of urinary tract infections, when transported to an acidic medium such as the 
urinary bladder it undergoes protonation which results in a complete breakdown of the 
molecule to yield ammonia and the antibacterial agent formaldehyde (Figure 1).
[15]
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N Acidic pH
O
H H
+ NH3
Methenamine (inactive) Formaldehyde Ammonia 
Figure 1. Formation of the antibacterial agent formaldehyde from Methenamine 
predrug at acidic pH. 
 
Prontosil, the first sulfa drug and a predrug of sulfanilamide was found to be therapeutically 
effective against microorganisms only in vivo, and not in vitro. Upon administration it is 
metabolized by the enzyme azo-reductase to provide sulfanilamide (Figure 2).
[16]
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Figure 2. Metabolic activation of Prontosil by azo-reductase. 
 
The predrug approach was not utilized till the mid twentieth century when Parke-Davis 
Company was intentionally used it for the first time to modify the chemical structure of the 
antibacterial agent chloramphenicol aiming at improving its bitter taste and poor water 
solubility. 
 
Two predrugs of chloramphenicol were synthesized by Parke-Davis Company; 
chloramphenicol sodium succinate with improved water solubility for IV, IM, and 
ophthalmic administrations, and the bitterless chloramphenicol palmitate formulated into 
suspension for pediatrics and geriatrics administration (Figure 3).
[2, 17] 
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Figure 3. Conversion of chloramphenicol predrugs to their active parent drug, 
chloramphenicol. 
 
The mutual predrug approach (codrug approach) was utilized in the case of sulfasalazine. 
Sulfasalazine is a colon selective mutual predrug, of  5-aminosalicylic acid (5-ASA) and 
sulfapyridine given for the treatment of ulcerative colitis.
[18]
 This mutual predrug was the first 
sulfa drug to be utilized in inflammatory bowel disease after its development in the mid 
twentieth century. It consists of 5-ASA attached to sulfapyridine through a diazo bond 
(Figures 4 and 5). In vivo, the diazo bond is easily cleaved by bacterial azo-reductases found 
in the colon. Studies on this mutual predrug revealed that 5-ASA moiety was found to be 
therapeutically active compound, while sulfapyridine is believed to act solely as a carrier 
moiety to deliver 5-ASA to the affected area of the lower gastrointestinal tract.
[19, 20]
 This 
approach has a significant advantage since the mutual predrug undergoes a metabolic 
cleavage to provide 5-ASA prior to its absorption, thus preventing its systemic absorption and 
aids in concentrating the active parent drug at the site of action. Although sulfapyridine has 
proved to be an excellent targeting carrier for 5-ASA to the colon, it gave rise to many 
adverse effects as a result of its systemic toxicity.  
 
Due to this disadvantage, another interesting mutual predrug of 5-ASA, olsalazine, has been 
emerged. Olsalazine (OSZ) is a dimer of 5-ASA, where a molecule of 5-ASA is attached to 
another similar molecule via an azo linkage. When this dimer reaches the large intestine, it 
undergoes cleavage to furnish two molecules of 5-ASA for every molecule of olsalazine 
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administered (Figure 5). This strategy completely eliminates the side effects associated with 
sulfasalazine, targets 5-ASA to the colon, and improves the bioavailability of 5-ASA. 
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Figure 4. Metabolic conversion of the mutual predrug, sulfasalazine, to sulfapyridine 
and 5-ASA. 
 
Balsalazine was also synthesized by linking 5-ASA and 4-aminobenzoyl-b-alanine (Figure 5) 
which has shown good efficiency with fewer side effects than SASP.
[21]
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Figure 5: Another azo bond containing predrugs OSZ (2 units of 5-ASA linked 
together) and balsalazine (5-ASA linked to 4-aminobenzoyl-b-alanine). 
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A large number of carrier linkage predrugs are designed to be activated by metabolic 
esterases. A variety of esterases is distributed throughout the whole body and differs in their 
specificity.  
 
The most important group of enzymes involved in ester bioactivation is carboxylesterases 
(CESs). This kind of enzymes is a multi-gene whose genes are localized in the endoplasmic 
reticulum (ER) of different tissues. The CESs catalyze the hydrolysis of a variety of ester- 
and amide-containing predrugs to the corresponding parent drugs. CESs show ubiquitous 
tissue expression profiles with the highest levels of CESs activity present in the liver 
microsomal site.
[21]
 Therefore, the potential for their substrates to become involved in drug-
drug interactions is expected to be negligible.
[22]
 Example of antibacterial predrug that is 
activated by this type of esterases is pivampicillin (Figure 6). 
 
N
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O H N
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O
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O
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H
Estrases
Pivampicillin
Ampicillinprodrug
active drug  
Figure 6: Activation of pivampicillin via carboxylesterase. 
 
Other examples of antibacterials predrugs that were obtained to improve oral bioavailability 
and clinical profile for their parent active forms are carbenicillin, carfecillin (phenyl ester) 
and carindacillin (indanyl ester) (Figure 7).
[23]
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Figure 7: Chemical structures of carbenicillin, carfecillin and cardinacillin. 
 
Acyloxy and alkyl or [(alkoxycarbonyl) oxy] methyl esters are another class of carboxylic 
acid esters. Practically, acyloxy and alkyl [(alkoxycarbonyl) oxy] methyl esters both are 
cleaved in vivo in an efficient manner.
[2]
 Acyloxyalkyl esters of benzyl penicillin are 
enzymatically cleaved in a fast manner into their active parent drugs. The rapid cleavage rate 
is due to the spacing provided by the acyloxycarbonyl linker.
[24]
 On the other hand, alkyl 
ester predrugs of other β-lactam antibacterial agents are slowly converted into their active 
parent drugs due to the crowding surroundings the carbonyl group contained in their 
structures (Figure 8).
[2]
  
                       
Drug
O
OOO
Steric hindrance is minimized
around the carbonyl group due to 
spacing provided by the 
    acyloxymethyl ester moiety
Acyloxymethyl ester moiety
 
Figure 8: An illustration of the steric hindrance around the carbonyl group in the 
acyloxymethyl ester moiety. 
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Sultamicillin is a member of this class in which the irreversible β-lactamase inhibitor, 
sulbactam, is attached through an ester linkage to an ampicillin molecule to provide a mutual 
predrug. One of the advantages of this mutual predrug is the fact that it possesses a 
synergistic effect.
[25]
 and upon an oral administration it is completely hydrolyzed to 
equimolar proportions of sulbactam and ampicillin, thereby acting as an efficient mutual 
predrug (Figure 9).
[26]
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Figure 9: A conversion of sultamicillin to ampicillin and sulbactam. 
  
Hetacillin is synthesized from a condensation of ampicillin with acetone.
[27]
 and is considered 
as an example of 4- imidazolidinones (Figure 10) predrugs.  It was designed to overcome the 
polymerization phenomenon.
[28]
 associated with ampicillin. Polymerization of ampicillin 
occurs at high concentrations as a result of the intermolecular nucleophilic attack by the free 
amino terminal present in ampicillin molecule on the beta lactam ring of an adjacent 
molecule. Hetacillin predrug exhibits a six-fold increase in stability compared to ampicillin 
which is achieved by the equilibrium obtained between the drug and the predrug. In a later 
stage, the predrug converts back to ampicillin within 11 minutes. Using this approach the oral 
bioavailability of ampicillin was slightly increased.
[29]
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Figure 10: Chemical structures of hetacillin and ampicillin. 
 
Another example of antibacterial predrug is clindamycin phosphate. Upon parenteral 
administration of clindamycin, an extremely irritating sensation at the injection site occurs.
[30]
 
However, an administration of clindamycin phosphate ester predrug overcomes this problem 
due to improved aqueous solubility with subsequent in vivo efficient release of clindamycin 
(Figure 11).
[31]
 Consequently, clindamycin phosphate was approved for parenteral and topical 
administrations.
[32]
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P
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Clindamycin phosphate  
Figure 11: Chemical structures of clindamycin and its predrug, clindamycin phosphate. 
                                                                                                             
As it is well known, ampicillin, acid resistant semi-synthetic penicillin, has a high polarity 
with a variable and low oral bioavailability.  In order to achieve an efficient therapeutic 
activity, large oral doses are required, therefore considerable amounts of the antibacterial can 
reach the colon and modify colonic flora, and this generally leads to a high incidence of 
diarrhea.  
 
In order to overcome this problem attempts were made to modify its structure by an addition 
of ester group to its carboxyl terminal thus obtaining a predrug with improved oral 
absorption. 
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This ester predrug remains in the gut in inactive form and it is less likely to cause diarrhea, 
however, after absorption, it undergoes a rapid hydrolysis to furnish its active parent drug. 
There are three ester predrugs of ampicillin that are currently available (Figure 12): (1) 
Pivampicillin (pivaloyloxymethyl ester) releases formaldehyde and pivalic acid, (2) 
talampicillin (pthalidylthiazolidine ester) releases 2-carboxybenzaldehyde and (3) 
bacampicillin (ethoxycarbonvloxvethvl ester) releases acetaldehyde, carbon dioxide and 
ethanol.  The Plasma concentrations of ampicillin attained with these esters are up to five 
times higher than those seen after oral administration of ampicillin. The advantages of  
pivampicillin over the other two ester predrugs that it undergoes the least hydrolysis in the 
intestine before absorption.
[33] 
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Figure 12: Chemical structures of ampicillin ester predrugs. 
 
On the other hand, the orally administered cephalosporin predrugs have dual-esters.  Those 
are fairly hydrophilic drugs of third and fourth generations that include aminotiazol and 
methoxamine groups in their structure, that responsible for their broad spectrum bactericidal 
activity and resistance to beta-lactamases. 
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For example cefuroxime axetil (Figure 13), cefpodoxime proxetil and cefetamet 
pivoxil (Figure 14) predrugs are more lipophilic, and administered orally with greater 
bioavailability than their parent active drugs. After absorption, enzymatic hydrolysis occur , 
followed by a chemical rearrangement due to the electronic characteristics of the 
intermediary formed, thus releasing their active parent drugs.
[34]
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Figure 13: Cefuroxime axetil structure and its conversion into cefuroxime. 
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Figure 14: Cefpodoxime proxetil and cefetamet pivoxil structures being bioactivated 
into cefpodoxime and cefetamet. 
 
Erythromycin is a macrolide antibiotic, consists of 14-atom lactone to which two sugars are 
bonded. One of these sugars features an amino group which gives the drug the characteristic 
of a weak base that enables the formation of salts with organic acids. Although this drug is 
effective against a wide variety of microorganisms its bitter taste and instability in an acidic 
medium prevented its therapeutic use. 
 
Erythromycin stearate is a salt able to reduce the bitterness and, especially, increases the 
stability of the drug in an acidic medium. The lauryl sulfate salt of propionyl erythromycin 
ester, more commonly known as erythromycin estolate, is the well-known erythromycin 
predrug. This predrug is obtained from an esterification between the hydroxyl group of the 
amino sugar present in erythromycin and propionic acid carboxyl group. The bitterness of 
erythromycin is reduced by the esterification process and the oral absorption of the drug is 
increased. The active parent drug, erythromycin, is released into the bloodstream or muscle 
tissue after the action of esterases on its ester predrugs (Figure 15).
[34]
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Figure 15: Conversion of erythromycin stearate and erythromycin estolate into 
erythromycin. 
 
The Desire to develop a ‗dual-action cephalosporin‘ antibiotics that intended to expel potent 
antibacterial agents when acted upon by βL producing bacterial strains set the phase for 
designing cephalosporin-containing anticancer predrugs.
[35]
 Cephalosporin nitrogen mustard 
derivatives are an example of one of the first reported cephalosporin-based anticancer 
predrug that is activated by broad scale βL enzymes from Enterobacter cloacae. Extension of 
this work includes predrugs of other nitrogen mustards, doxorubicin, mitomycin C, vinca 
alkaloid, and paclitaxel and carboplatinum analogues. A diverse array of βL enzymes from E. 
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cloacae, E. coli, and B. cereus were used to activate these predrugs.
[35, 36]
 The chemical 
structures of some of the predrugs activated by βL enzymes are shown in Figure 16. 
 
One of the first reported in vivo activities of mAb- βL system was cephalosporine- vinca 
alkaloid predrug using a βL enzyme from E. cloacae;  the predrug was linked to mAb Fab‘ 
fragment such that recognition of CEA, TAG-72 and KS1/4 antigens on tumor tissues was 
observed. Therapeutic effects of mAb- enzyme conjugate in combination with vinca predrug 
were studied in models of human colorectal carcinoma in nude mouse and it was found in all 
cases to be superior to naked drug therapy.
[35]
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Figure 16: Chemical structures of CCM and C-mel predrugs that are activated by βL 
enzymes. 
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Bitterless amoxicillin and cephalexin predrugs 
A large number of commonly used antibiotics suffer unpleasant taste and some of them are 
characterized with bitter sensation. For instance, the β –lactam antibacterial agents such as 
amoxicillin, cephalexin and cefuroxime axetil have extremely bitter taste which is hard to 
eliminate. The bitter sensation of drugs has a negative effect on the patient compliance 
especially pediatric and geriatric patients who have difficulty in swallowing whole tablets or 
when small doses are given. Moreover, it is also even difficult for those patients to administer 
antibacterial suspensions due to their better and unpleasant sensation.
[37-49]
 
 
It is believed that the bitter taste of those antibacterials is as a result of the binding of the 
antibacterial agent to the active site of a bitter taste receptor via intermolecular forces These 
forces are most likely due to the formation of hydrogen bonding or ionic bonding between the 
amido (in cefuroxime) or amino (in amoxicillin and cephalexin) group to the active site/s of 
the bitter taste receptor/s. 
 
In the past few years we have investigated a large number of intramolecular processes that 
were advocated to understand enzyme catalysis. Using different quantum molecular 
mechanics methods we have unraveled the mechanisms of a large number of intramolecular 
processes. Continuing our studies on how to use these enzyme models as linkers in predrugs 
design we have utilized the acid-catalyzed hydrolysis of N-alkyl maleamic acids (Kirby‘s 
enzyme model).
[50-63]
 to design and synthesize predrugs of amoxicillin, cephalexin and 
cefuroxime axetil. Our goal was to provide drugs with relatively good antibacterial activities 
and lacking the bitter sensation associated with the use of their parent drugs. 
 
Based on our previously reported DFT calculations and on experimental data for the acid-
catalyzed hydrolysis of several N-alkylmaleamic acid amides.
[64-102]
 two amoxicillin and 
cephalexin predrugs were proposed (Figures17 and 18, respectively). As shown in Figures17 
and 18, the antibacterial predrugs, amoxicillin ProD 1 and cephalexin ProD 1 molecules are 
composed of an amide acid promoiety, containing a carboxylic acid group (hydrophilic 
moiety) and the rest of the antibacterial predrug molecule (a lipophilic moiety).                                                                                                      
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Figure 17: Acid-catalyzed hydrolysis of amoxicillin ProD 1. 
 
The combination of both, the hydrophilic and lipophilic groups provides a predrug entity with 
a moderate HLB and potentially with a high permeability. The HLB value of the predrug is 
determined upon the pH of the target physiological environment. In the stomach where the 
pH is in the range of 1-2, it is expected that amoxicillin ProD1 and cephalexin ProD1 will be 
in a free carboxylic acid form whereas in the blood circulation where the pH is 7.4 a 
carboxylate anion is expected to be predominant form. Our strategy was to prepare 
amoxicillin ProD 1 and cephalexin ProD 1 as sodium or potassium carboxylates due to their 
high stability in neutral aqueous medium.  
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Figure 18: Acid-catalyzed hydrolysis of cephalexin ProD 1. 
 
The conversion of amoxicillin ProD 1 and cephalexin ProD 1 to their parent drugs were 
carried out in four different aqueous media: 1 N HCl, buffer pH 2.5, buffer pH 5 and buffer 
pH 7.4. Under the experimental conditions the two antibacterial predrugs intraconverted to 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1520 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
release the parent drugs as was determined by HPLC analysis. For both amoxicillin and 
cephalexin predrugs, at constant temperature and pH the hydrolysis reaction displayed strict 
first order kinetics as the kobs was quite constant and a straight line was obtained on plotting 
log concentration of residual predrug verves time. The rate constant (kobs) and the 
corresponding half-lives (t1/2) for amoxicillin ProD 1 and cephalexin ProD 1 in the different 
media were calculated from the linear regression equation obtained from the correlation of 
log concentration of the residual predrug verses time. The kinetic data for amoxicillin ProD 
1and cephalexin ProD 1 are listed in Tables 1 and 2, respectively. It is worth noting that 1N 
HCl, pH 2.5 and pH 5 were selected to examine the intraconversion of amoxicillin ProD 1 
and cephalexin ProD 1 in the pH as of stomach, since the mean fasting stomach pH of adult is 
approximately 1-2.5. Furthermore, environment of buffer pH 5 mimics that of beginning 
small intestine route, whereas pH 7.4 was selected to determine the intraconversion of the 
tested predrugs in blood circulation system. Acid-catalyzed hydrolysis of both, amoxicillin 
ProD 1 and cephalexin ProD 1 was found to be much higher in 1N HCl than at pH 2.5 and 5. 
On the other hand, at pH 7.4, both predrugs amoxicillin ProD 1 and cephalexin ProD 1 were 
quite stable and no release of the parent drugs was observed. At pH 5 the hydrolysis of both 
predrugs amoxicillin ProD 1 and cephalexin ProD 1 was too slow. This is because the pKa of 
amoxicillin ProD 1 and cephalexin ProD 1 is in the range of 3-4, it is expected that at pH 5 
the anionic form of the predrug will be dominant and the percentage of the free acidic form 
that undergoes an acid-catalyzed hydrolysis will be relatively low. At 1N HCl and pH 2.5 
most of the predrug will exist as the free acid form and at pH 7.4 most of the predrug will be 
in the anionic form. Thus, the discrepancy in rates at the different pH buffers.   
                                                                                                               
Table 1: Kinetics of amoxicillin ProD 1 in 1N HCl and at pH 2, 5 and 7.4 
 
 
 
 
 
Table 2: Kinetics of cephalexin ProD 1 in 1N HCl and at pH 2, 5 and 7.4 
 
 
 
 
t 1/2  (h) k obs (h
-1
) Medium 
2.5 2.33x10 
-4
 1 N HCl 
7 9.60 x10 
-5
 Buffer pH 2.5 
81 7.55x10
-6
 Buffer pH 5 
---- No reaction Buffer pH 7.4 
t 1/2  (h) k obs (h
-1
) Medium 
2.4 2.41x10 
-4
 1 N HCl 
14 4.17x10 
-5
 Buffer pH 2.5 
--- No reaction Buffer pH 5.5 
--- No reaction Buffer pH 7.4 
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SUMMARY AND CONCLUSIONS 
In this mini review we have covered most of antibacterial predrugs which were designed and 
synthesized during the past few decades aiming to provide compounds with potent 
antibacterial activity but without the side effects associated with their parent drugs. 
 
Almost all antibacterial predrugs documented in this mini-review were obtained by the 
classic predrug approach, by which the active antibacterial agent is linked to a linker or 
another active drug directly, or via a spacer and upon in vivo administration is cleaved by 
enzyme-catalyzed reaction to liberate the active parent drug. The enzyme-catalyzed activation 
has many disadvantages due to many intrinsic and extrinsic factors that can affect the rate of 
the predrug cleavage. For example, the activity of many predrug-activating enzymes may be 
varied due to genetic polymorphisms, age-related physiological changes, or drug interactions, 
leading to variation in clinical effects. Therefore, there is a necessity to invoke a new 
approach in which the predrug‘s cleavage is independent on the source and nature of the 
metabolic enzyme. 
 
The novel computational approach which has been utilized by Karaman‘s group considers 
linking a designed linker to an active drug, such as amoxicillin, that has poor bioavailability 
and/or bitter sensation, which upon exposure to physiologic environment releases the parent 
drug via intramolecular chemical reaction in the absence of metabolic enzymes. With the 
possibility of designing predrugs with a variety of linkers, the cleavage rate of the predrug 
can be controlled and the disadvantages associated with the metabolic enzymes will be 
eliminated.  
 
Advances must be made and achieved in comprehending the chemistry of many organic 
processes that can be effectively used to enable the development of even more types of 
predrugs. The understanding of organic reaction mechanisms of certain processes, 
particularly intramolecular reactions, will be the next major milestone in the field of predrug 
design.  
 
REFERENCES 
1. Albert, A. Chemical aspects of selective toxicity. Nature., 1958; 182: 421–2  
2. Stella, V.; Borchardt, R.; Hageman, M.; Oliyai, R.; Maag, H. & Tilley, J. Prodrugs: 
challenges and Rewards Published by AAPS Press and Springer 2007; 1-2. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1522 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
3. Stella, V.J. & Nti-Addae, K.W.  Prodrug strategies to overcome poor water solubility. 
Adv Drug Deliv Rev., 2007; 59(7): 677-94. 
4. Rautio, J.; Kumpulainen, H.; Heimbach, T.; Oliyai, R.; Oh,  D.; Jarvinen, T. & 
Savolainen, J. Prodrugs: design and clinical applications. Nat Rev Drug Discov., 2008; 
7(3): 255-70. 
5. Müller, C.E. Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low 
Solubility. Chemistry & Biodiversity., 2009;  6(11): 2071-83. 
6. Dahan, A.; Khamis, M.; Agbaria, R.; Karaman, R. Targeted prodrugs in oral drug 
delivery: the modern molecular biopharmaceutical approach. Expert Opinion on Drug 
Delivery, 2012; 9(8): 1001-1013. 
7. Karaman, R.; Fattash, B.; Qtait, A. The future of prodrugs – design by quantum 
mechanics methods. Expert Opinion on Drug Delivery., 2013; 10: 713–729. 
8. Karaman, R. Prodrugs design based on inter- and intramolecular processes. Chem. Biol. 
Drug.Des., 2013; 82: 643–668. 
9. Karaman, R. Prodrugs Design by Computation Methods- A New Era. Journal of Drug 
Designing., 2013 ; 2 : e113. doi:10.4172/2169-0138.1000e113. 
10. Karaman, R. From Conventional Prodrugs to Prodrugs Designed By Molecular Orbital 
Methods, Eds.  ul Haq, Z.; Madura, J. D.; Alvarez-Ibarra, A.; Goursot, A.; Köster, A. M.; 
Vela, A., ... & Guo, Z. Frontiers in Computational Chemistry. Bentham Publisher., 2015; 
1-77. 
11. Karaman, R. (Editor), Prodrugs Design Based On Inter- And Intramolecular Processes, 
in: Prodrugs Design – A New Era, Karaman, R. editor, Nova Science Publishers, Inc. NY, 
USA, 2014, pp 1-76. 
12. Abu-Jaish, A.; Jumaa, S.; Karaman, R., Prodrugs Overview , in: Prodrugs Design – A 
New Era,  Karaman R. editor, Nova Science Publishers, Inc. NY, USA, 2014, pp 77-102. 
13. Fattash, B.; Karaman, R., Chemical Approaches Used In Prodrugs Design, in: Prodrugs 
Design – A New Era, Karaman, R. (Editor),  Nova Science Publishers, Inc. NY, USA, 
2014, pp 103-138 
14. Karaman, R. Using predrugs to optimize drug candidates. Expert opinion on drug 
discovery., 2014; 9(12): 1405-1419. 
15. Testa, B. Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. Curr Opin Chem 
Biol., 2009; 13(3): 338-44. 
16. Albert, A. Selective Toxicity : The PhysicoChemical Basis of Therapy. 7 ed. New York: 
Chapman and Hall 1985. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1523 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
17. Glazko, A.J.; Carnes, H.E.; Kazenko, A.; Wolf, L.M. & Reutner, T.F. Succinic acid esters 
of chloramphenicol. Antibiot Annu., 1957; 5: 792-802. 
18. Azadkhan, A.K.; Truelove, S.C. & Aronson, J.K. The disposition and metabolism of 
sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol., 1982; 13(4): 
523-8. 
19. Peppercorn, M.A. & Goldman,  P. Distribution studies of salicylazosulfapyridine and its 
metabolites. Gastroenterology., 1973; 64(2): 240-5. 
20. Peppercorn, M.A. & Goldman, P. The role of intestinal bacteria in the metabolism of 
salicylazosulfapyridine. J Pharmacol Exp Ther., 1972; 181(3): 555-62. 
21. Hosokawa, M.; Maki, T. & Satoh, T. Characterization of molecular species of liver 
microsomal carboxylesterases of several animal species and humans. Arch Biochem 
Biophys., 199;  277(2): 219-27. 
22. Liederer, B.M. & Borchardt, R.T. Enzymes involved in the bioconversion of ester-based 
prodrugs. J Pharm Sci., 2006; 95(6): 1177-95. 
23. Modr, Z.; Dvovacek, K.; Janku, I.; Krebs, V. Pharmacokinetics of carfecillin and 
carindacillin. International journal of clinical pharmacology and biopharmacy, 1997; 
15(2): 81-3.  
24. Jansen, A. B.; Russell, T.J. Some Novel Penicillin Derivatives. Journal of the Chemical 
Society., 1965; 65: 2127-32.  
25. Bhosle, D.; Bharambe, S. D.; Gairola, N.; Dhaneshwar, S. Mutual prodrug concept: 
Fundamentals and applications. Indian journal of pharmaceutical sciences., 2006; 68( 3): 
286-94. 
26. English, A. R.; Girard, D.; Haskell, S. L. Pharmacokinetics of sultamicillin in mice, rats, 
and dogs. Antimicrobial agents and chemotherapy., 1984; 25(5): 599-602.  
27. Tsuji, A.; Yamana, T. Kinetic approach to the development in beta-lactam antibiotics. II. 
Prodrug. (I). Simultaneous determination of hetacillin and ampicillin, and its application 
to the stability of hetacillin in aqueous solutions. Chemical & pharmaceutical bulletin., 
1974; 22(10): 2434-43. 
28. Schwartz, M. A.; Hayton, W. L. Relative stability of hetacillin and ampicillin in solution. 
Journal of pharmaceutical sciences., 1972; 61(6): 906-9. 
29. Jusko, W. J.;  Lewis, G. P. Comparison of Ampicillin and HetacillinPharmacokinetics in 
Man. J Pharm Sci., 1973; 62: 69-76. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1524 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
30. Novak, E.; Wagner, J.G.; Lamb, D. J. Local and systemic tolerance, absorption and 
excretion of clindamycin hydrochloride after intramuscular administration. International 
journal of clinical pharmacology, therapy, and toxicology., 1970;  3(3): 201-8. 
31. Riebe, K.W.; Oesterling, T.O. Parenteral development of clindamycin-2-phosphate. 
Bulletin of the Parenteral Drug Association., 1972; 26(3): 139-46. 
32. Cambazard, F. Clinical efficacy of Velac, a new tretinoin and clindamycin phosphate gel 
in acne vulgaris. Journal of the European Academy of Dermatology and Venereology : 
JEADV, 1998, 11 Suppl 1, S20-7; discussion S8-9. Epub 1999/01/19. 
33. Waller, D.G.; George, C.F. Prodrugs. British Journal of Clinical Pharmacology., 1989; 
28(5): 497-507. 
34. Parise, F. R., et al., Prodrugs available on the Brazilian pharmaceutical market and their 
corresponding bioactivation pathways. Brazilian Journal of Pharmaceutical Sciences., 
2010; 46: 393-420. 
35. Senter, P.D.; Springer, C.J. Selective activation of anticancer prodrugs by monoclonal 
antibody-enzyme conjugates. Advanced drug delivery reviews., 2001; 53: 247-64.  
36. Melton, R.G.; Sherwood, R.F. Antibody-enzyme conjugates for cancer therapy. Journal 
of the National Cancer Institute., 1996;  88: 153-65.  
37. Karaman, R. Prodrugs for Masking the Bitter Taste of Drugs. Chapter 12 in Application 
of Nanotechnology in Drug Delivery, Editor: Ali Demir Sezer, InTech - Open Access 
Publisher, 2014, pp 399-445. 
38. Karaman, R. Computationally designed enzyme models to replace natural enzymes in 
prodrug approaches. J Drug Design., 2012; e111. 
39. Karaman, R. Prodrug design vs. drug design. J Drug Design., 2013; 2: e114. 
40. Karaman, R.; Bruice, T. C. Synthesis and Characterization of the First Water Soluble 
Porphyrin Dimer.  J. Org. Chem., 1991; 56: 3470-3472. 
41. Karaman, R. computationally designed prodrugs for masking the bitter taste of drugs. J 
Drug Design., 2012; 1: e106. 
42. Karaman, R. Prodrugs design by computation methods-a new era. Journal of Drug 
Designing., 2013; 1: e113. 
43. Karaman, R. The Prodrug Naming Dilemma. Drug Des., 2013; 2: e115. 
44. Karaman, R. A Solution to Aversive Tasting Drugs for Pediatric and Geriatric Patients. 
Drug Des., 2013; 2: e116. 
45. Karaman, R. The future of prodrugs designed by computational chemistry. Drug Des., 
2012; 1: e103. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1525 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
46. Almarsson, O.; Karaman, R.; Bruice, T.C. The Kinetic Importance of Conformations of 
Nicotinamide Adenine Dinucleotide in the Reactions of Dehydrogenase Enzymes. J. Am. 
Chem. Soc., 1992 ; 114 : 8702-8704. 
47. Jeon, S.; Almarsson, O.; Karaman, R.; Blasko, A.; Bruice, T. C. Symmetrical and 
Unsymmetrical Quadruply Aza Bridged Closely-Interspaced Cofacial Bis-5,10,15,20-
Tetra-phenylporphyrins 4. Structure and Conformational Effects on Electrochemistry and 
the Catalysis of Electrochemical Reductions of Dioxygen by Doubly, Triply and 
Quadruply N, N-Dimethylene Sulfonamide Bridged Dimeric Bis (Cobalt 
tetraphenylporphyrin).  Inorg. Chem., 1993; 32: 2562-2569. 
48. Karaman, R. Design of Prodrugs to Replace Commonly Used Drugs Having Bitter 
Sensation. World Journal of Pharmaceutical Research., 2015; 4(2): 49-58. 
49. Hejaz, H.; Karaman, R.; Khamis, M. Computer-assisted design for paracetamol masking 
bitter taste prodrugs. Journal of molecular modelling., 2012; 18(1); 103-114. 
50. Kirby, A. J.; Hollfelder, F. From Enzyme Models to Model Enzymes, RSC Publishing, 
Cambridge UK, 2009, pp 1-273. 
51. Barber, S. E.; Dean, K. E. S. & Kirby, A. J. A mechanism for efficient proton-transfer 
catalysis. Intramolecular general acid catalysis of the hydrolysis of 1-arylethyl ethers of 
salicylic acid. Can. J. Chem., 1999; 77: 792-801. 
52. Kirby, A. J. & Lancaster, P. W. structure and efficiency in intramolecular and enzymatic 
catalysis. Catalysis of amide hydrolysis by the carboxy-group of substituted maleamic 
acids.  J. Chem. Soc., Perkin Trans., 1972; 2: 1206-1214. 
53. Kirby, A. J.; de Silva, M. F.; Lima, D.; Roussev, C. D. & Nome, F. Efficient 
intramolecular general acid catalysis of nucleophilic attack on a phosphodiester. J. Am. 
Chem. Soc., 2006; 128: 16944-16952. 
54. Kirby, A. J. & Williams, N. H. Efficient intramolecular general acid catalysis of enol 
ether hydrolysis. Hydrogen-bonding stabilization of the transition state for proton transfer 
to carbon. J. Chem. Soc., Perkin Trans., 1994; 2: 643-648. 
55. Kirby, A. J. & Williams, N. H. Efficient intramolecular general acid catalysis of vinyl 
ether hydrolysis by the neighbouring carboxylic acid group. J. Chem. Soc. Chem. 
Commun., 1991; 1643-1644. 
56. Kirby, A. J. Enzyme Mechanisms, Models, and Mimics. Angewandte Chemie 
International Edition in English., 1996; 35: 706-724. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1526 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
57. Fife, T. H. & Przystas, T. J. Intramolecular general acid catalysis in the hydrolysis of 
acetals with aliphatic alcohol leaving groups. J. Am. Chem. Soc., 1979; 101: 1202-1210. 
58. Kirby, A. J. Efficiency of proton transfer catalysis in models and enzymes. Acc. Chem. 
Res., 1997; 30: 290-296. 
59. Menger, F. M. & Ladika M. Fast hydrolysis of an aliphatic amide at neutral pH and 
ambient temperature. A peptidase model. J. Am. Chem. Soc., 1988; 110: 6794-6796. 
60. Menger, F. M. On the source of intramolecular and enzymatic reactivity. Acc. Chem. 
Res., 1985; 18: 128-134. 
61. Menger, F. M.; Chow, J. F.; Kaiserman H. & Vasquez P. C. Directionality of proton 
transfer in solution. Three systems of known angularity. J. Am. Chem. Soc., 1983; 105: 
4996-5002. 
62. Menger, F. M.; Galloway, A. L. & Musaev D. G. Relationship between rate and distance. 
Chem. Commun., 2003; 2370-2371. 
63. Menger, F. M. An alternative view of enzyme catalysis. Pure Appl. Chem., 2005; 77: 
1873–187. 
64. Karaman, R. Computational‐Aided Design for Dopamine Prodrugs Based on Novel 
Chemical Approach. Chemical biology & drug design., 2011; 78(5): 853-86. 
65. Karaman, R. Analysis of Menger‘s ‗spatiotemporal hypothesis‘. Tetrahedron Letters., 
2008; 49(41): 5998-6002. 
66. Karaman, R. Cleavage of Menger‘s aliphatic amide: a model for peptidase enzyme solely 
explained by proximity orientation in intramolecular proton transfer. Journal of Molecular 
Structure: THEOCHEM., 2009; 910(1): 27-33. 
67. Karaman, R. The efficiency of proton transfer in Kirby‘s enzyme model, a computational 
approach. Tetrahedron Letters, 2010; 51(16): 2130-2135. 
68. Karaman, R., & Pascal, R. A computational analysis of intramolecularity in proton 
transfer reactions. Org. Biomol. Chem., 2010; 8(22): 5174-5178. 
69. Karaman, R. A general equation correlating intramolecular rates with ‗attack ‗parameters: 
distance and angle. Tetrahedron Letters., 2010; 51(39): 5185-5190. 
70. Karaman, R. Analyzing the efficiency of proton transfer to carbon in Kirby‘s enzyme 
model—a computational approach. Tetrahedron Letters., 2011; 52(6): 699-704. 
71. Karaman, R. Analyzing the efficiency in intramolecular amide hydrolysis of Kirby‘s N-
alkylmaleamic acids–A computational approach. Computational and Theoretical 
Chemistry., 2011; 974(1): 133-142. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1527 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
72. Karaman, R. A new mathematical equation relating activation energy to bond angle and 
distance: a key for understanding the role of acceleration in lactonization of the trimethyl 
lock system. Bioorganic chemistry., 2009; 37(1): 11-25. 
73. Karaman, R. Reevaluation of Bruice‘s proximity orientation. Tetrahedron Letters., 2009; 
50(4): 452-456. 
74. Karaman, R. Accelerations in the lactonization of trimethyl lock systems are due to 
proximity orientation and not to strain effects. Organic Chemistry International., 2009. 
doi: 10.1155/2009/240253. 
75. Karaman, R. The gem-disubstituent effect—a computational study that exposes the 
relevance of existing theoretical models. Tetrahedron Letters., 2009; 50(44): 6083-6087. 
76. Karaman, R. Analyzing Kirby‘s amine olefin—a model for amino acid ammonia lyases. 
Tetrahedron Letters., 2009; 50(52): 7304-7309. 
77. Karaman, R. The effective molarity (EM) puzzle in proton transfer reactions. Bioorganic 
chemistry., 2009; 37(4): 106-110. 
78. Karaman, R. Effects of substitution on the effective molarity (EM) for five membered 
ring-closure reactions–A computational approach. Journal of Molecular Structure: 
Theochem., 2010; 939(1): 69-74. 
79. Karaman, R. The effective molarity (EM) puzzle in intramolecular ring-closing reactions. 
Journal of Molecular Structure: Theochem., 2010; 940(1): 70-75. 
80. Menger, F. M., & Karaman, R. A singularity model for chemical reactivity. Chemistry-A 
European Journal., 2010; 16(5): 1420-1427. 
81. Karaman, R. The effective molarity (EM)–a computational approach. Bioorganic 
chemistry., 2010; 38(4): 165-172. 
82. Karaman, R.; Blasko, A.; Almarsson, O.; Arassasingham, R.; Bruice T. C. Symmetrical 
and Unsymmetrical Quadruply Aza Bridged Closely-Interspaced Cofacial Bis-5,10,15,20-
Tetra-Phenylporphyrins 2.Synthesis, Characterization and Conformational Effects of 
Solvents.  J. Am. Chem. Soc., 1992; 114: 4889-4898 . 
83. Karaman, R. Proximity vs. strain in intramolecular ring-closing reactions. Molecular 
Physics., 2010; 108(13): 1723-1730. 
84. Karaman, R. The role of proximity orientation in intramolecular proton transfer reactions. 
Computational and Theoretical Chemistry., 2011; 966(1): 311-321. 
85. Karaman, R. Analyzing Kemp‘s amide cleavage: A model for amidase enzymes. 
Computational and Theoretical Chemistry., 2011; 963(2): 427-434. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1528 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
86. Karaman, R., Ghareeb, H., Dajani, K. K., Scrano, L., Hallak, H., Abu-Lafi, S., ... & Bufo, 
S. A. Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the 
treatment of bleeding conditions. Journal of computer-aided molecular design., 2013; 
27(7): 615-635. 
87. Karaman, R., Dajani, K. K., Qtait, A., & Khamis, M. Prodrugs of Acyclovir–A 
Computational Approach. Chemical biology & drug design., 2012; 79(5): 819-834. 
88. Karaman, R., Dajani, K., & Hallak, H. Computer-assisted design for atenolol prodrugs for 
the use in aqueous formulations. Journal of molecular modelling., 2012; 18(4): 1523-
1540. 
89. Karaman, R.; Qtait, A.; Dajani, K.K.; Abu Lafi, S. Design, Synthesis, and In Vitro 
Kinetics Study of Atenolol Prodrugs for the Use in Aqueous Formulations. The Scientific 
World Journal 2014, Article ID 942703, 7 pages.  
90. Karaman, R. Prodrugs for masking bitter taste of antibacterial drugs—a computational 
approach. Journal of molecular modelling., 2013; 19(6): 2399-2412. 
91. Karaman, R.; Dokmak, G.; Bader, M.; Hallak, H.; Khamis, M.; Scrano, L.; & Bufo, S. A. 
Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis—a 
computational approach. Journal of molecular modelling., 2013; 19(1): 439-452. 
92. Karaman, R.; Bruice, T. C. Unusual Behavior of meso-Substituted 5, 10, 15, 20- 
Tetraphenylporphyrin Diacid towards Oxygen Bronsted Bases. Inorg. Chem., 1992; 31: 
2455-2459. 
93. Karaman, R. Prodrugs of aza nucleosides based on proton transfer reaction. Journal of 
computer-aided molecular design., 2010; 24(12): 961-970. 
94. Karaman, R., & Hallak, H. Computer‐Assisted Design of Pro‐drugs for Antimalarial 
Atovaquone. Chemical biology & drug design., 2010; 76(4): 350-360. 
95. Karaman, R. Antimalarial Atovaquone Prodrugs Based on Enzyme Models-Molecular 
Orbital Calculations Approach. Antimalarial Drug Research and Development, Banet, A 
C. & Brasier, P. Ed, 2013; 1-67. 
96. Karaman, R.; Fattash, B.; Mecca, G.; & Bader, M. Computationally designed atovaquone 
prodrugs based on Bruice‘s enzyme model. Current computer-aided drug design., 2014; 
10(1): 15-27. 
97. Karaman, R.; Amly, W.; Scrano, L.; Mecca, G.; & Bufo, S. A. Computationally designed 
prodrugs of statins based on Kirby‘s enzyme model. Journal of molecular modelling., 
2013; 19(9): 3969-3982. 
www.wjpps.com                                Vol 4, Issue 08, 2015.                                             
           
 
1529 
Rafik et al.                                    World Journal of Pharmacy and Pharmaceutical Sciences 
98. Karaman, R.; Karaman, D.; & Zeiadeh, I. Computationally-designed phenylephrine 
prodrugs–a model for enhancing bioavailability. Molecular Physics., 2013; 111(21): 
3249-3264. 
99. Abu-Jaish, A.; Mecca, G.; Jumaa, S.; Thawabteh, A.; Karaman, R. Mefenamic acid 
Prodrugs and Codrugs- Two Decades of Development. World Journal of Pharmaceutical 
Research., 2015; 4(6): 2408-2429. 
100. Karaman, R. Computationally Designed Prodrugs Based on Enzyme Models‖ Aperito 
Journal of Drug Designing and Pharmacol., 2015; 2: 111. 
http://dx.doi.org/10.14437/AJDDP-2-111. 
101. Horani, W.; Thawabteh, A.; Scrano, L.; Bufo, S.A.; Mecca, G.; Karaman, R. Anti-
cancer Prodrugs-Three Decades of Design. World Journal of Pharmacy & Pharmaceutical 
Sciences World Journal of Pharmacy & Pharmaceutical Sciences., 2015; 4(7): 1751-1779. 
102. Dweib, K.; Jumaa, S.; Thawabteh, A.; Scrano, L.; Bufo, S.A.; Mecca, G.; Karaman, R. 
Diclofenac Codrugs and Prodrugs-Three Decades of Design. World Journal of Pharmacy 
& Pharmaceutical Sciences., 2015; 4(7): 1960-1982. 
 
 
 
